Activating NRAS mutations can be found at up to 18% frequency and are mutually exclusive with BRAF mutations.38 Remarkably, GNAQ and GNA11 mutations are virtually nonexistent in CM, which differs from uveal melanoma.54 The KIT gene encodes a receptor tyrosine kinase which promotes cell survival and growth and is found to be mutated in nearly 2% of CM.55KIT-mutated melanomas are shown to be sensitive to imatinib, a tyrosine kinase inhibitor including c-kit. The gene discussed is BRAF; the disease is cutaneous mastocytosis.